Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

y of pirfenidone was reassuring. The principal side effects experienced by patients in the studies were gastrointestinal discomfort and photo-sensitivity, both of which were manageable in the majority of patients."

Dr. Noble concluded, "The efficacy and safety findings of CAPACITY were generally consistent with those observed in the Phase 3 study in IPF patients conducted by Shionogi in Japan. Collectively, these three Phase 3 studies give us a very good sense of the impact that pirfenidone has on the progression of IPF over at least one year."

About CAPACITY and RECAP

The CAPACITY program consisted of two multinational, randomized, double-blind, placebo-controlled Phase 3 trials, named CAPACITY 1 and CAPACITY 2, designed to evaluate the safety and efficacy of pirfenidone in IPF patients with mild to moderate impairment in lung function. The primary endpoint of both trials was change in percent predicted Forced Vital Capacity (FVC) after 72 weeks of treatment evaluated with a nonparametric rank ANCOVA analysis. Both trials enrolled patients in North America, Europe and Australia with roughly 75% of the total 779 patients enrolled in North America.

CAPACITY 1 enrolled a total of 344 patients. Patients were randomized 1:1 to receive a total daily dose of 2403 mg pirfenidone, or placebo. CAPACITY 2 enrolled a total of 435 patients, and patients were randomized 2:2:1 to receive a total daily dose of 2403 mg pirfenidone, or placebo, or a total daily dose of 1197 mg pirfenidone, respectively, administered in three divided doses. The lower dose of pirfenidone in CAPACITY 2 provided safety and tolerability data. The pre-specified statistical analysis plan did not call for this low-dose group to be used in any analyses of efficacy. The pooled analyses of the primary and secondary efficacy outcome measures were based on a combined analysis of the 2403 mg group compared with the placebo group across
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
(Date:12/19/2014)... separating membrane market has witnessed robust development with ... albeit as a later starter. In 2012, the size of ... RMB12 billion, with the proportion worldwide soaring to 16.3%. It ... market will continue its growth rate by around 20% in ... jump to roughly RMB25 billion. An integrated membrane ...
(Date:12/17/2014)... December 17, 2014 Los beneficios ... un alto nivel de gasto en investigación y desarrollo ... (finalizado el 30 de septiembre de 2014) ZEISS aumentó ... millones de euros (año anterior: 4.190 millones de euros) ... Las ganancias (EBIT) crecieron un 14 por ciento, a ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3ZEISS confirma su posición en un entorno difícil 2
... ALTO, Calif., Oct. 1 Telik, Inc. (Nasdaq: TELK ... a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination ... nonsmall cell lung cancer (NSCLC) in a leading peer reviewed ... Vol. 4, No. 10. Data on this study were ...
... , MOUNTAIN VIEW, Calif., Oct. 1 IRIDEX Corporation ... FlexFiber(TM) a laser fiber probe intended for effective delivery ... procedures. Introduced at the 2009 American Academy of ... , this consumable product represents an increase in IRIDEX, ...
Cached Medicine Technology:Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer 2IRIDEX Introduces New ENT Laser Delivery Devices at AAO-HNSF Annual Meeting 2
(Date:12/20/2014)... The holidays can be anything but joyous for people ... candles and other allergy triggers. "The dust from ... packed away in dank basements or dusty attics is ... Rachna Shah, an affiliate faculty member at Loyola University ... release. Shah, who is also an allergist at ...
(Date:12/20/2014)... 20, 2014 The Doctor’s Office Urgent Care ... better part of a decade. They’ve treated over 40,000 ... faster healthcare alternative to the Paramus area. ... new additions to their staff of top-notch board certified physicians: ... MD. These new doctors will work tirelessly to ...
(Date:12/20/2014)... New York (PRWEB) December 20, 2014 ... continue to move forward in U.S. courts, Bernstein ... study which suggests that children treated with the ... hormone linked to breast development and lactation. The ... at 34 children and adolescents who began treatment ...
(Date:12/20/2014)... 20, 2014 The aftermath of the November ... stir, not only in Hollywood, but worldwide. As ... the ripples of that attack are starting a finger-pointing game ... risk. But they are not the only ones affected, ... in for some embarrassing times ahead, agents and lawyers could ...
(Date:12/20/2014)... 2014 Developers of FCPX ... new plugin for Final Cut Pro X entitled TranSlice ... 5 allows users to create hand drawn text animations ... Austin, CEO of Pixel Film Studios. “TranSlice Volume 5 ... maintaining an easy to use interface.” , TranSlice Volume ...
Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... , , , NEW YORK, ... is available in its catalogue. , , ... http://www.reportlinker.com/p0131247/Lung-Cancer-Therapeutics.html , , ... Cancer Therapeutics in Millions of US$. The US market for Non-Small ...
... ... Diego, CA adds General Motors and Qualcomm to the program! , ... Portland, ME (PRWEB) September 8, 2009 -- Image Sensors ... San Diego, CA. The 3rd annual international event will address the latest trends and technologies ...
... , , , Will ... , , NEW YORK, Sept. 8 MARK ... of Lighthouse International, the 104-year-old non-profit leader in vision healthcare, research, ... in healthcare management, will start in his new role on September ...
... , ... head back to school , ... (PRWEB) September 8, 2009 -- As the unemployment rate in Canada holds steady at 8.6%, more ... the recession. , , , ,CDI College, a career college with 13 campus locations across Canada, ...
... The New York Football Giants are asking their fans to ... EAST RUTHERFORD, N.J., Sept. 8 We heard you bleed BLUE! ... ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20090908/DC71650LOGO ) , , On ... with the American Red Cross to host a blood drive. The ...
... Sept. 8 Give an Hour(TM), a national nonprofit organization providing ... their loved ones, announces results of its August 2009 survey and ... survey in May 2009. , , Give an ... effectiveness and to determine how programs and services can be adapted ...
Cached Medicine News:Health News:Reportlinker Adds Lung Cancer Therapeutics Report 2Health News:Reportlinker Adds Lung Cancer Therapeutics Report 3Health News:Reportlinker Adds Lung Cancer Therapeutics Report 4Health News:Reportlinker Adds Lung Cancer Therapeutics Report 5Health News:Reportlinker Adds Lung Cancer Therapeutics Report 6Health News:Reportlinker Adds Lung Cancer Therapeutics Report 7Health News:Reportlinker Adds Lung Cancer Therapeutics Report 8Health News:Reportlinker Adds Lung Cancer Therapeutics Report 9Health News:Reportlinker Adds Lung Cancer Therapeutics Report 10Health News:Image Sensors 2009 Offers Promotional Discount on Machine Vision and Wireless Power Summits 2Health News:Image Sensors 2009 Offers Promotional Discount on Machine Vision and Wireless Power Summits 3Health News:Mark G. Ackermann Is Named New President and CEO of Lighthouse International 2Health News:Mark G. Ackermann Is Named New President and CEO of Lighthouse International 3Health News:Fall 2009 Sees Spike in Enrollments at CDI College 2Health News:New York Giants to Host American Red Cross Blood Drive 2Health News:Give an Hour(TM)'s Volunteer Mental Health Professionals Provide Nearly $1.7 Million in Services to Iraq and Afghanistan Veterans, Families, and Communities 2
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: